US 12,030,881 B2
Ion channel modulators
Andrew Mark Griffin, L'lle Bizard (CA); Brian Edward Marron, Ada, MI (US); Gabriel Martinez Botella, Wayland, MA (US); and Kiran Reddy, Boston, MA (US)
Assigned to Praxis Precision Medicines, Inc., Boston, MA (US)
Filed by PRAXIS PRECISION MEDICINES, INC., Cambridge, MA (US)
Filed on Mar. 4, 2022, as Appl. No. 17/687,002.
Application 17/687,002 is a continuation of application No. 16/887,897, filed on May 29, 2020, granted, now 11,279,700.
Claims priority of provisional application 62/855,294, filed on May 31, 2019.
Prior Publication US 2022/0204505 A1, Jun. 30, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01)
CPC C07D 471/04 (2013.01) 21 Claims
 
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound represented by Formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
R1 is selected from the group consisting of —CR2R3R4, a monocyclic C3-6 cycloalkyl, and a 4- to 7-membered monocyclic heterocyclyl, wherein said cycloalkyl and heterocyclyl are optionally substituted with one or more Ra;
R2 is a C1-4 haloalkyl or a monocyclic C3-6 cycloalkyl optionally substituted with one or more Rb;
R3 is selected from the group consisting of hydrogen, a C1-4 alkyl, and a C1-4 haloalkyl;
R4 is selected from the group consisting of hydrogen, a C1-4 alkyl, and a C1-4 haloalkyl;
R5 is a halogen;
R6 is a C1-4 haloalkyl or a C3-6 monocyclic cycloalkyl, wherein said cycloalkyl is optionally substituted with one or more Rc;
t is 1 or 2; and
Ra, Rb, and Rc are each independently selected from the group consisting of a halogen, a C1-4 alkyl, a C1-4 haloalkyl, a C1-4 alkoxy, and a C1-4 haloalkoxy, wherein the pharmaceutical composition is in a unit dosage form.